Three names are expected to have strong setups this week: Zeta Global (ZETA), Boston Scientific (BSX), and Summit Therapeutics (SMMT). Each stock has its own catalyst, and analysts see room for more gains as earnings, new product launches, and pipeline updates drive interest across tech, medical devices, and biotech.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Using the TipRanks Stock Screener tool, we picked these three stocks because they have received a “Strong Buy” consensus rating from analysts. Also, these stocks have more than 40% upside potential in the next twelve months.
Let’s look at why ZETA, BSX, and SMMT are the best stocks to watch this week. (Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.)
1. Zeta Global (ZETA)
Analysts remain upbeat on Zeta as the company keeps gaining share in the marketing tech space. Demand for its AI‑driven ad tools continues to grow, and recent results showed strong revenue growth and better margins. Several firms raised their price targets after the latest earnings call. They believe Zeta is winning larger enterprise deals and expanding its platform faster than expected.
Overall, ZETA stock has a Strong Buy consensus rating based on 12 Buys and one Hold assigned in the last three months. At $28.31, the average Zeta Global stock price target implies a 47.51% upside potential.
2. Boston Scientific (BSX)
Boston Scientific manufactures innovative, minimally invasive medical devices. The company’s pipeline, especially in heart and surgical care, gives it a long runway for growth. Recent product approvals and strong procedure volumes have helped BSX beat expectations. Also, the company is expected to keep posting double-digit earnings growth, making it an attractive defensive pick in a volatile market.
Wall Street’s consensus rating for BSX stock is Strong Buy based on 26 Buys and one Hold. The average analyst price target of $87.64 implies an upside potential of 56.82% from the current levels.
3. Summit Therapeutics (SMMT)
Summit continues to draw attention thanks to its late‑stage cancer drug, which could be a major value driver if trial results stay strong. The stock has been volatile, but Wall Street sees meaningful upside tied to upcoming clinical updates and partnership opportunities.
On TipRanks, analysts have a Strong Buy consensus rating on SMMT stock based on 10 Buys and three Holds assigned in the past three months. Further, the average Summit price target of $30.83 per share implies 92.53% upside potential.
